Clinical Trials Logo

Muscular Dystrophies clinical trials

View clinical trials related to Muscular Dystrophies.

Filter by:

NCT ID: NCT05575648 Completed - Clinical trials for Duchenne Muscular Dystrophy

Dual Task in Duchenne Muscular Dystrophy

Start date: September 6, 2022
Phase: N/A
Study type: Interventional

This study was planned to determine the effects of the dual-task performance of children with DMD with motor dysfunction and varying degrees of cognitive impairment compared to their healthy peers, to compare the dual-task performance of children with different functional levels, and to determine the relationship between parameters that may affect dual-task performance.

NCT ID: NCT05564962 Completed - Clinical trials for Duchenne Muscular Dystrophy

Quality and Independence of Gait Classification Scale for DMD (QIGS-DMD)

Start date: January 19, 2021
Phase:
Study type: Observational

The aim of this study was to develop a reliable and valid gait classification scale for Duchenne Muscular Dystrophy (QIGS-DMD). The items of the QIGS-DMD were designed based on the literature review considering existing functional classification scales, gait scales, and the opinions of the physiotherapists who were expertized in rehabilitation of patients with DMD. Content validity was determined based on the opinions of a total of ten expert physiotherapists. Videos were recorded during gait of 69 children with DMD and inter- and intra-rater reliability were examined. Criterion validity was determined according to the relationship between QIGS-DMD and Motor Function Measure (MFM) and Vignos Lower Extremity Rating Scale (VLERS).

NCT ID: NCT05559710 Completed - Clinical trials for Duchenne Muscular Dystrophy

Motor Imagery in Duchenne Muscular Dystrophy

Start date: June 20, 2022
Phase:
Study type: Observational

Motor imagery (MI) can be defined as a dynamic process in which the person is mentally stimulated without performing the given motor movement. Studies of imagery; demonstrated that it alters a person's ability to learn, performance skills, and important cognitive skills (self-efficacy, self-confidence, effort, motivation). In recent years, it has been shown that motor imagery techniques are used for therapeutic purposes as a current neurorehabilitation approach and that imagery can have positive effects on improving motor activity and functions. However, it has been reported that the biggest difficulty in the use of imagery techniques is the inability to determine to what extent the individual can perform mental representation of movements. For this reason, it is thought that it is necessary to evaluate the motor imagery ability first in order to identify the patients who are suitable for motor imagery training. The Kinesthetic and Visual Imagery Questionnaire (KVIQ) is a motor imagery questionnaire developed for individuals with limited mobility for different reasons. The questionnaire assesses both the visual and kinesthetic dimensions of motor imagery. of the KVIQ; It has also been shown in the literature that it is a valid and reliable questionnaire that enables the appropriate evaluation of motor imagery in different neurological disease groups such as Multiple Sclerosis, Parkinson's disease, and stroke. However, the literature When examined, no evidence was found about the motor imagery ability of individuals with Duchenne muscular dystrophy (DMD). It is foreseen that KVIQ will be especially suitable for patients with DMD of different functional levels, since all its items have been developed to be applied to people with limited physical mobility or physically disabled people in a sitting position. Therefore, in this study, it is aimed to investigate the validity and reliability of the Kinesthetic and Visual Imagery Questionnaire for patients with DMD.

NCT ID: NCT05558813 Not yet recruiting - Clinical trials for Duchenne Muscular Dystrophy

Natural History of Duchenne Muscular Dystrophy Cardiomyopathy (DMD-CMP)

DMD-CMP
Start date: November 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to describe the progression of tissular and functional myocardial abnormalities in patients with Duchenne muscular dystrophy using cardiac magnetic resonance imaging and blood biomarkers assays.

NCT ID: NCT05549999 Completed - Clinical trials for Duchenne Muscular Dystrophy

Cultural Adaptation, Validity, and Reliability of the Turkish Version of North Star Ambulatory Assessment

Start date: November 1, 2022
Phase:
Study type: Observational

The aim of this study is to translate the "North Star Ambulatory Assessment (NSAA)" scale into Turkish and make its cultural adaptation and to demonstrate the reliability and validity of the Turkish version in patients with ambulatory DMD. For the translation into Turkish, validity and reliability of the NSAA, necessary permission was obtained from the developer of the questionnaire, Prof. Dr. Francesco Muntoni, via e-mail. In the study, first of all, the translation and cultural adaptation process will be completed, and then reliability-validity studies will be carried out.

NCT ID: NCT05548556 Active, not recruiting - Clinical trials for Facioscapulohumeral Muscular Dystrophy (FSHD)

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

MANOEUVRE
Start date: February 7, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

NCT ID: NCT05540860 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

Start date: October 24, 2022
Phase: Phase 2
Study type: Interventional

The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.

NCT ID: NCT05528757 Terminated - Clinical trials for Limb-Girdle Muscular Dystrophy ; Subtypes 2A, 2B, and 2I

Limb-Girdle Video Assessment

Start date: June 20, 2022
Phase:
Study type: Observational

The purpose of this study is to develop a new remote-based video assessment outcome measure for Limb-Girdle Muscular Dystrophy (LGMD) trials. The overall objectives for this study are: 1. Identify domains and tasks meaningful to participants with a Limb-Girdle Muscular Dystrophy (LGMD) for development of the LGVA, including considerations for subtype heterogeneity and functional subgroup branching; 2. Determine the feasibility and reliability of the LGVA with test-retest of the LGVA Video Capture Manual; 3. Assess and refine the LGVA Video Capture Manual to ensure standardization and incorporate feedback from participants; 4. Collect source material videos using the LGVA Video Capture Manual to support the development of scorecards for the LGVA.

NCT ID: NCT05524883 Recruiting - Clinical trials for Duchenne Muscular Dystrophy (DMD)

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

DELIVER
Start date: August 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the safety, tolerability, and dystrophin protein levels in muscle tissue following multiple intravenous (IV) doses of DYNE-251 in participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The study consists of 3 periods: a multiple-ascending dose (MAD) / placebo-controlled period (24 weeks), an open-label period (24 weeks) and a long-term extension period (96 weeks).

NCT ID: NCT05516745 Recruiting - Clinical trials for Duchenne Muscular Dystrophy (DMD)

E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home"

E-PULMoDMD
Start date: March 20, 2021
Phase: N/A
Study type: Interventional

Duchenne muscular dystrophy (DMD) is the most common, progressive, irreversible muscular dystrophy. The pulmonary function is crucial for the duration of life in this disease. The European Respiratory Society is currently focused on digital health, seeking to define the realistic innovations for digital respiratory medicine to support professionals and patients during the COVID-19 pandemic. This study aimed to investigate whether it is possible to monitor pulmonary function at home by using an individual electronical spirometry system in children with Duchenne muscular dystrophy DMD. The second aim of the study is the implementation of respiratory telerehabilitation and the assessment of its impact on pulmonary function (FVC).